Pasithea Therapeutics Corp. (KTTA) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Quote Panel

Updated April 26, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

Relative Strength

KTTA

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-3.45
vs -0.17

Q4.22

N/A

-3.00
vs 0.12

Q1.23

N/A

-211.05
vs -0.07

Q2.23

N/A

-2.88
vs -0.08

Q3.23

N/A

-2.87
vs -3.45

Q4.23

N/A

-4.85
vs -3.00

Q1.24

N/A

-3.70
vs -211.05

Q2.24

N/A

-3.71
vs -2.88

Q3.24

N/A

-2.87
vs -2.87

Q4.24

N/A

-2.41
vs -4.85

Sales Growth

YoY

Current

Estimates

Q3.22

NA

218.6K vs NA

Q4.22

+1498%

240.7K vs 15.1K

Q1.23

-100%

NA vs 13.7K

Q2.23

-100%

NA vs 13.6K

Q3.23

-100%

NA vs 218.6K

Q4.23

+306%

976.3K vs 240.7K

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

-100%

NA vs 976.3K

Return on Equity

QoQ

Q1.23

-703%

-7.03
vs -0.09

Q2.23

-11%

-0.11
vs -7.03

Q3.23

-13%

-0.13
vs -0.11

Q4.23

-22%

-0.22
vs -0.13

Q1.24

-19%

-0.19
vs -0.22

Q2.24

-24%

-0.24
vs -0.19

Q3.24

-17%

-0.17
vs -0.24

Q4.24

-21%

-0.21
vs -0.17

Institutionnal Ownership

QoQ

Q1.22

7

7
vs 6

17%

Q2.22

8

8
vs 7

14%

Q3.22

8

8
vs 8

NA

Q4.22

11

11
vs 8

38%

Q1.23

12

12
vs 11

9%

Q2.23

12

12
vs 12

NA

Q3.23

12

12
vs 12

NA

Q4.23

8

8
vs 12

-33%

Earnings Growth

Latest News

KTTA

globenewswire.com

6 hours ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

KTTA

globenewswire.com

7 hours ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

KTTA

globenewswire.com

7 hours ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

KTTA

globenewswire.com

7 hours ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

KTTA

globenewswire.com

8 hours ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

KTTA

globenewswire.com

18 hours ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules